🎙 Hosted by Adam Diament, Registered Patent Attorney | Partner, Nolan Heimann LLP

When is an invention too obvious to be patented?

In this episode, Adam Diament unpacks one of the most important (and misunderstood) concepts in patent law: obviousness. He focuses on the recent case of Vanda Pharmaceuticals vs. Teva Pharmaceuticals, where the Federal Circuit used the “reasonable expectation of success” standard—ultimately invalidating Vanda’s patent for Hetlioz.

Tune in to learn:

• The difference between “reasonable expectation of success” and “predictable results”
• How biotech and pharma inventions are especially affected
• Why the Supreme Court’s refusal to hear the case cements this standard—for now
• What this means for inventors and attorneys going forward

📌 Mentioned in this episode:
– Vanda v. Teva
– Hetlioz (treatment for sleep disorders)
– Supreme Court’s 2024 cert denial
– Prior episodes on obviousness: Ep. 3, 47, 48, 49, 143

🎧 Subscribe to the full series at nolanheimann.com/podcast

🧠 Knowledge is power—especially when it’s not obvious.